New York Life Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

New York Life Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.78M	Buy	+88,339	New	+$2.61M	0.02%	492
2024 Q2	–	Sell	-22,640	Closed	-$361K	–	971
2024 Q1	$361K	Buy	+22,640	New	+$341K	﹤0.01%	1197
2023 Q1	–	Sell	-68,427	Closed	-$1.27M	–	1242
2022 Q4	$1.27M	Buy	68,427 +7,340	+12%	+$113K	0.01%	592
2022 Q3	$784K	Buy	61,087 +4,834	+9%	+$57.3K	0.01%	639
2022 Q2	$394K	Buy	+56,253	New	+$413K	﹤0.01%	980

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

GCM

Gables Capital Management Miami, Florida $277M AUM 41.87% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

New York Life Investment Management's CPRX Position: Q2 2026 in Review

New York Life Investment Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 88,339 shares worth $2.78M. The stake represents 0.02% of the portfolio and ranks #492 among its holdings. This is a return to the name: New York Life Investment Management previously reported a position in CPRX as recently as Q1 2024.

New York Life Investment Management first reported a position in CPRX in Q2 2022 and has held it in 5 quarters since. 175 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

New York Life Investment Management held 88,339 shares of Catalyst Pharmaceutical worth $2.78M as of Q2 2026.
Catalyst Pharmaceutical was a new New York Life Investment Management position in Q2 2026.
Catalyst Pharmaceutical made up 0.02% of New York Life Investment Management's portfolio in Q2 2026, its #492 holding.
New York Life Investment Management first reported a position in Catalyst Pharmaceutical in Q2 2022 and has held it in 5 quarters since.
175 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.